Graves N M, Holmes G B, Fuerst R H, Leppik I E
College of Pharmacy, University of Minnesota, Minneapolis 55455.
Epilepsia. 1989 Mar-Apr;30(2):225-9. doi: 10.1111/j.1528-1157.1989.tb05458.x.
Felbamate (FBM) is a novel antiepileptic drug (AED) undergoing clinical trials in the United States. During a double-blind, cross-over clinical trial, patients received concomitant phenytoin (PHT) and carbamazepine (CBZ). Dosages of PHT and CBZ were adjusted to maintain serum concentrations +/- 20 and +/- 25% of baseline values. All patients required a PHT dosage decrease of 10-30% during active FBM treatment to maintain stable concentrations. CBZ serum concentrations decreased significantly in patients receiving active FBM. The mean decrease was 1.3 micrograms/ml and occurred in 30 of 32 patients. Therefore, FBM apparently causes a bidirectional effect on the serum concentrations of PHT and CBZ when all three drugs are taken concomitantly.
非氨酯（FBM）是一种正在美国进行临床试验的新型抗癫痫药物（AED）。在一项双盲、交叉临床试验中，患者同时服用苯妥英（PHT）和卡马西平（CBZ）。调整PHT和CBZ的剂量以维持血清浓度在基线值的±20%和±25%范围内。在FBM活性治疗期间，所有患者都需要将PHT剂量降低10 - 30%以维持稳定浓度。接受活性FBM治疗的患者中，CBZ血清浓度显著降低。平均降低量为1.3微克/毫升，32名患者中有30名出现此情况。因此，当三种药物同时服用时，FBM显然会对PHT和CBZ的血清浓度产生双向影响。
